In this episode, we’re diving into the latest research on hydrocortisone use in critically ill patients with severe community-acquired pneumonia (CAP). It's a treatment many clinicians reach for—but does it actually make a difference in survival? According to a new study, the answer might not be as strong as we hoped. While hydrocortisone may help shorten the duration of vasopressor support, it doesn’t significantly reduce mortality. We break down what this means for clinical practice, patient care, and the future of treating severe pneumonia. Tune in for key takeaways and why more research is still needed before we rewrite the playbook.
ResusX:Podcast